Translation

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

Non-consolidated Financial Results for the Six Months of the Fiscal Year Ending September 30, 2026 (Under Japanese GAAP)

May 14, 2026

Company name:	PRISM BioLab Co., LTD
Stock exchange listings:	Tokyo Stock Exchange
Stock code:	206A
URL:	https://prismbiolab.com/ja/
Representative:	Dai Takehara, Representative Director
Contact:	Koji Ando, Manager of Administration Division
TEL:	+81 466 53 8383
Scheduled date to commence dividend payment:	None
Scheduled date for submission of interim report:	May 14, 2026
Preparation of supplementary material on financial results:	Yes
Holding of financial results briefing:	Yes

(Amounts of less than one million yen are rounded down.)

1. Non-consolidated Financial Results for the Six Months of the Fiscal Year Ending September 30, 2026 (from October 01, 2025 to March 31, 2026)

(1) Non-consolidated operating results (Cumulative)

(Percentages indicate YoY changes)

	Revenue		Operating profit		Ordinary profit		Net income	
Six months ended	¥ millions	%	¥ millions	%	¥ millions	%	¥ millions	%
March 31, 2026	253	15.8	(584)	-	(560)	-	(603)	-
March 31, 2025	218	89.4	(460)	-	(432)	-	(474)	-

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
March 31, 2026	(16.34)	-
March 31, 2025	(13.06)	-

(Note) Diluted earnings per share is not presented, as there are potential shares but the company recorded a net loss per share for the quarter.

(2) Non-consolidated financial positions

	Total assets	Equity	Equity to total assets ratio
As of	¥ millions	¥ millions	%
March 31, 2026	2,586	2,129	81.8
September 30, 2025	3,085	2,708	87.6

(Reference) Owner's equity

For the six months ended September 30, 2026: 2,116 ¥ millions

For the fiscal year ended September 30, 2025: 2,701 ¥ millions

2. Cash dividends

	Annual dividends per share				
	End of first quarter	End of second quarter	At the end of the third quarter	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended September 30, 2025	-	0.00	-	0.00	0.00
Fiscal year ending September 30, 2026	-	0.00			
Fiscal year ending September 30, 2026 (Forecast)			-	0.00	0.00

(Note) Presence or absence of revisions from the most recently announced dividend forecast: None

3. Non-consolidated Earnings Forecasts for the Fiscal Year Ending September 30, 2026 (from October 01, 2025 to September 30, 2026)

Regarding the forecasts for the fiscal year ending September 2026, we have not disclosed them as it is not possible to make a reasonable estimate at this time.

* Notes

(1) Application of accounting treatments specific to the preparation of the semi-annual financial statements : None

(2) Changes in accounting policies, changes in accounting estimates, retrospective restatement

(i) Changes in accounting policies based on revisions of accounting standard : None

(ii) Changes in accounting policies other than (i) above : None

(iii) Changes in accounting estimates : None

(iv) Retrospective restatement : None

(3) Number of shares issued (common stock)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of March 31, 2026	36,964,000 shares
As of September 30, 2025	36,810,000 shares

(ii) Number of treasury shares at the end of the period

As of March 31, 2026	- shares
As of September 30, 2025	- shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended March 31, 2026	36,914,648 shares
Six months ended March 31, 2025	36,334,525 shares

Note: The second quarter (interim) financial results report is not subject to review by certified public accountants or audit firms.

* Notes regarding the appropriate use of forecasts and other special items

(Cautionary Statement Regarding Forward-Looking Statements)

The forward-looking statements, including earnings forecasts, contained in this document are based on information currently available to the Company and certain assumptions that are deemed reasonable. They are not intended as a guarantee of achievement by the Company. Actual results may differ significantly due to various factors.

(How to Obtain Supplementary Materials on financial results and Contents of Financial Results Briefing)

The Company plans to hold financial results briefings for institutional investors, analysts, and general investors on May 18, 2026 (Monday). The materials used at the briefing will be promptly posted on the Company's website after the event.

Interim Non-consolidated Financial Statements

(1) Interim Non-consolidated Balance Sheets

(¥ thousands)

	For the fiscal year ended September 30, 2025	For the Six Months of the fiscal year ending September 30, 2026
Assets		
Current assets		
Cash and deposit	2,915,572	2,454,487
Prepaid expenses	54,414	55,829
Consumption taxes refund receivable	52,828	15,005
Other	16,075	15,421
Total current asset	3,038,891	2,540,745
Non-current assets		
Property, plant, and equipment		
Buildings	23,431	23,936
Accumulated depreciation and impairment	(23,431)	(23,936)
Buildings, net	0	0
Machinery and equipment	22,609	15,827
Accumulated depreciation and impairment	(22,609)	(15,827)
Machinery and equipment, net	0	0
Tools, furniture and fixtures	307,918	340,836
Accumulated depreciation and impairment	(307,917)	(340,836)
Tools, furniture and fixtures, net	0	0
Total property, plant and equipment, net	0	0
Investment Other assets		
Other	46,800	45,579
Total investment and other assets	46,800	45,579
Total non-current assets	46,801	45,580
Total assets	3,085,692	2,586,325

(¥ thousands)

	For the fiscal year ended September 30, 2025	For the Six Months of the fiscal year ending September 30, 2026
Liabilities		
Current liabilities		
Accounts payable	78,720	89,864
Accrued expenses	8,283	11,414
Income taxes payable	25,960	24,664
Contract liabilities	236,589	300,223
Deposits received	7,637	10,698
Provision for bonuses	12,888	12,914
Total current liabilities	370,080	449,778
Non-current liabilities		
Asset retirement obligations	6,781	6,777
Total non-current liabilities	6,781	6,777
Total liabilities	376,862	456,555
Net assets		
Shareholders' equity		
Share capital	1,730,911	1,739,755
Capital surplus	3,347,231	3,356,075
Retained earnings	(2,376,435)	(2,979,744)
Total shareholders' equity	2,701,707	2,116,086
Share acquisition rights	7,122	13,682
Total net assets	2,708,830	2,129,769
Total liabilities and net assets	3,085,692	2,586,325

(2) Interim Non-consolidated Statements of Income

(¥ thousands)

	For the six months ended From October 1, 2024 until March 31, 2025	For the six months ended From October 1, 2025 until March 31, 2026
Revenue	218,676	253,211
Cost of sales	167,209	171,510
Gross profit	51,466	81,701
Selling, general and administrative expenses	512,071	666,565
Operating loss (-)	(460,605)	(584,864)
Non-operating income		
Interest income	2,063	7,612
Foreign exchange gains	26,251	17,474
Other	27	7
Total non-operating income	28,342	25,094
Non-operating expenses		
Share issuance costs	113	384
Other	-	42
Total non-operating expenses	113	426
Ordinary loss (-)	(432,376)	(560,195)
Extraordinary losses		
Loss on retirement of fixed assets	-	99
Impairment losses	40,800	41,804
Total extraordinary losses	40,800	41,903
Interim loss before income taxes (-)	(473,177)	(602,099)
Income taxes - current	1,210	1,210
Total income taxes	1,210	1,210
Interim net loss (-)	(474,387)	(603,309)

(3) Interim Statement of Cash Flows

(¥ thousands)

	For the six months ended From October 1, 2024 until March 31, 2025	For the six months ended From October 1, 2025 until March 31, 2026
Cash flows from operating activities		
Interim loss before income taxes (-)	(473,177)	(602,099)
Share–based payment expenses	-	6,560
Increase (decrease) in provision for bonuses	5,335	25
Interest income	(2,063)	(7,612)
Foreign exchange loss	(30,478)	(19,584)
Share issuance costs	113	384
Loss on retirement of fixed assets	-	99
Impairment losses	40,800	41,804
Decrease (increase) in trade receivables	(29,904)	-
Increase (decrease) in contract liabilities	(183,999)	63,633
Other	(23,368)	52,221
Subtotal	(696,741)	(464,568)
Income taxes paid	(1,270)	(1,690)
Interest received	1,493	3,748
Cash flows from operating activities	(696,518)	(462,510)
Cash flows from investing activities		
Payments into time deposits	-	(1,500,000)
Purchase of property and equipment	(16,034)	(30,183)
Purchase of intangible assets	(2,300)	(6,500)
Proceeds from refund of leasehold and guarantee deposits	-	46,800
Payments of leasehold and guarantee deposits	(9)	(45,579)
Cash flows from investing activities	(18,343)	(1,535,462)
Cash flows from financing activities		
Proceeds from exercise of employee share options	29,079	17,303
Cash flows from financing activities	29,079	17,303
Effect of exchange rate change on cash and cash equivalents	30,478	19,584
Increase (decrease) in cash and cash equivalents	(655,303)	(1,961,085)
Cash and cash equivalents at the beginning of the period	4,392,022	2,915,572
Cash and cash equivalents at the end of the interim period	3,736,718	954,487